B+
Bull case
25%
Probability
Target price
$1,475.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
LLY
Eli Lilly andANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$1,328.08
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1,025.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+81.7
Score
AI commentary
The company-source gap is closed by Lilly's August 5 SEC earnings exhibit, which confirmed strong Q2 growth, higher guidance, regulatory progress, retatrutide milestones, and manufacturing investment. A market snapshot on August 7 showed shares at $1,185.71, down 0.58% on the session, but the available evidence does not establish the full earnings-day reaction. No verified post-print analyst revision was found, so sentiment remains constructive but tentative and better framed as monitoring than as a high-conviction chase. [#SEC-8K-2026-08-05]
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-05catalystQ2 results and higher 2026 guidanceMedium impact
Lilly reported Q2 2026 revenue of $23.0 billion, up 48%, and raised full-year revenue guidance to $85.0-$87.0 billion. Non-GAAP EPS was $8.38, though acquired IPR&D charges reduced reported and adjusted EPS. [#SEC-8K-2026-08-05]
2026-12-07eventInvestment Community MeetingMedium impact
Lilly has scheduled an Investment Community Meeting for December 7, 2026, providing a dated checkpoint for obesity demand, pipeline progress, manufacturing capacity, and capital allocation. [#SEC-8K-2026-04-30]
2027-08-08catalystRetatrutide registration package and planned 2027 filingHigh impact
Lilly reported positive data from three additional Phase 3 retatrutide trials and said the clinical package is complete to support global registrations, with a U.S. biologics license application planned for Q1 2027. [#SEC-8K-2026-08-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology